Xiaofeng Li, Ph.D.
CEO
Co-founder and member of board of director of Qx Therapeutics, Inc
Dr. Li is a seasoned executive, research & development leader focusing on drug discovery and development. He is strongly liaised with investors in the US and aboard.
He has more than 30 years of Research & Development and clinical development experience and has published 9 high level peer review articles. He is also inventor of 5 U.S. patents.
Dr. Li obtained his Ph.D. degree in Wuhan University in China and Postdoctoral Fellow at Weizmann Institute of Science in Israel.
Stanley Choy, MBA., CPA
Chief Financial Officer
Mr. Choy is an accomplished executive and entrepreneur with
over 25 years of cross-functional experience in the healthcare, biotechnology and professional services industries. He is a co-founder of SHY Therapeutics and provides financial and advisory services to early stage, start-up ventures.
Earlier in his career, Mr. Choy served as the Vice President, Finance and Administration at Kolltan Pharmaceuticals; a Yale affiliated
spin-out. Prior to joining Kolltan, Mr. Choy was the Chief Financial Officer for a leading New York/Boston based law firm. Before joining the legal industry, he spent eleven years at Pfizer, Inc., and held several senior finance management positions; he was instrumental in the integration of the Warner Lambert and Pharmacia acquisitions. Mr.
Choy started his career with Arthur Andersen and Company.
Mr. Choy is a seasoned and experienced business leader with 25 years of extensive hands on management expertise including financial and
strategic planning and global business development. He advises and participates on boards.
Mr. Choy serves as a director and co-chair of BioCT, the bioscience industry association for the State of Connecticut.
Mr. Choy is a CPA and has an MBA in Finance from Syracuse University and holds an accounting degree. He is certified in New York State and a member of the American Institute of CPAs.
Paul Chow, Ph.D. DABT
Chief Advisor of Toxicology
Dr. Chow has over 40 years of experience in the toxicology field. His vast experience including government agency (Department of National Health and Welfare, Canada); Big pharma companies (Wyeth, Roche); Medium size Pharma companies (Otsuka Pharmaceutical, Purdue Pharmaceutical, TaiGen Biotechnology) and CRO (Cleveland BioLabs).
He has played key role in the successful submission of 6 NDA’s and over 30 IND’s and numerous FDA briefing packages and annual reports. He has also played a leadership role in the successful out-licensing and in-licensing of a dozen NCE in various therapeutic areas
Dr. Chow obtained his Ph.D. degree in toxicology from the University of Michigan.
Todd Astor, MD
Senior Advisor of Medicine
Dr. Astor has over 20 years of experience in the medical field. Highly regarded internationally in the area of pulmonary diseases and graft transplants. His experience includes Fellowship in University of Colorado Health Sciences Center, Denver, CO, specialize in Pulmonary and Critical Care Medicine and Lung and Heart-Lung Transplantation.
He is currently appointed as Medical Director of Lung and Heart-Lung Transplantation in Massachusetts General Hospital, Boston, MA.
Dr. Astor obtained his medical degree from George Washington University School of Medicine, Washington, DC. Completed his residency in Cook County Hospital, Chicago, IL and Loyola University Medical Center Maywood, IL.
Dr. Astor also held academic position of Professor in Medicine in Ohio State University and Harvard University.
David Reinhold Brill, Ph.D.
Senior Advisor of Regulatory Affairs
Dr. Brill has over 35-years experience in the international pharmaceutical industry specializing in Regulatory Affairs. His experiences include the global development of drugs and biologics within a broad array of therapeutic targets culminating with successful registrations in the United States, the European Union, Japan, and the BRIC Emerging Markets (Brazil, Russia, India, and China).
Dr. Brill has both managed multidisciplinary project teams as well as taken on a "hands-on" approach to defining the global regulatory standards and registration / development strategies for projects ranging from early pre-IND activities through the successful registration and post-approval phases of development.
Dr. Brill obtained a Ph.D. degree in Biochemistry from Rutgers University in New Jersey and after several years of academic research and teaching in the areas of Nephrology and Hypertension, he entered the pharmaceutical industry. His initial experiences were focused on Quality Control / Quality Assurance / Manufacturing and Process Validation within a Manufacturing environment. He then transitioned into Rx Drug Regulatory Affairs with American Home Products (Ayerst Laboratories) and then spent 32-years at Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). as a Director of Regulatory Affairs.